Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.68 |
| ▸ | MMP9 | P14780 | 12/20 | 0.68 |
| ▸ | MMP1 | P03956 | 5/20 | 0.68 |
| ▸ | MMP14 | P50281 | 5/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.68 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | BMP1 | P13497 | 1/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945656 | 0.94 | MMP2 (0.77) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL7954067 | 0.91 | MMP2 (0.64) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL5033356 | 0.90 | MMP2 (0.69) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL7959937 | 0.90 | MMP2 (0.69) | MMP2MMP9MMP1MMP14ADAM17 | |
| Hydroxyamine SCHEMBL7688383 | 0.88 | MMP2 (0.67) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL5031591 | 0.85 | MMP2 (0.55) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL1379757 | 0.84 | MMP2 (0.52) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL5033750 | 0.84 | MMP2 (0.56) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL7954530 | 0.83 | MMP2 (0.68) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL7945731 | 0.81 | MMP2 (0.57) | MMP2MMP9MMP1MMP14ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |